贝抑素给药与细胞免疫的变化。

Bestatin administration and the change in cellular immunity.

作者信息

Yamagishi H, Naito K, Ueda Y, Itoi S, Kohnosu H, Kobayashi M, Kubo H, Matsuda A, Oka T

机构信息

2nd Dept of Surgery, Kyoto Prefectural University of Medicine, Japan.

出版信息

Biomed Pharmacother. 1991;45(2-3):117-20. doi: 10.1016/0753-3322(91)90131-c.

DOI:10.1016/0753-3322(91)90131-c

PMID:1912367

Abstract

The change in cellular immunity by Bestatin (ubenimex) treatment--30 mg/day orally--was investigated in 23 gastrointestinal cancer patients for: 1), functional T cell subsets; 2), IL-2 receptor; 3), PHA-induced blastogenesis; and 4), PPD skin reaction. The absolute number of helper T cells (Th) and cytotoxic T cells (Tc) increased in 74 and 79% of cases, respectively, compared with pretreatment values. On the other hand, the absolute number of suppressor T cells (Ts) decreased in 79% of cases. IL-2 receptor increased in 56% of patients, PHA blastogenesis increased in 67% of patients and PPD skin reaction was elevated in 75% of cases comparing to pretreatment values. These results suggest that Bestatin could increase cellular immunity in cancer patients.

摘要

研究了23例胃肠道癌患者口服贝司他汀（乌苯美司）（每日30毫克）后细胞免疫的变化，涉及以下方面：1）功能性T细胞亚群；2）白细胞介素-2受体；3）PHA诱导的淋巴细胞增殖；4）PPD皮肤反应。与治疗前相比，辅助性T细胞（Th）和细胞毒性T细胞（Tc）的绝对数量分别在74%和79%的病例中增加。另一方面，79%的病例中抑制性T细胞（Ts）的绝对数量减少。与治疗前相比，56%的患者白细胞介素-2受体增加，67%的患者PHA诱导的淋巴细胞增殖增加，75%的病例PPD皮肤反应增强。这些结果表明贝司他汀可增强癌症患者的细胞免疫。